Know More.

With the integration of the next-generation ClearSight finger cuff into the EV1000 clinical platform, a single platform can now be utilized with both noninvasive and minimally-invasive hemodynamic monitoring options, such as the FloTrac sensor. The ClearSight system also sends an analog pressure to visualize noninvasive BP on a bedside monitor. Edwards has taken this integrated system approach to protect the accuracy of the clinical information and the corresponding quality of patient care.

Helping to advance the care of the acutely ill for 40 years, Edwards Lifesciences seeks to provide the valuable information you need, the moment you need it. Through continuing collaboration with you, ongoing education and our never-ending quest for advancement, our goal is to delivery clarity in every moment.

References

For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices placed on the European market, meet the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC, and bear the CE-marking of conformity. Edwards, Edwards Lifesciences, the stylized E logo, ccNexfin, ClearSight, EV1000, FloTrac and Nexfin are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. © 2014 Edwards Lifesciences Corporation. All rights reserved. AR1578
The ClearSight system extends continuous hemodynamic monitoring to a broader patient population, including your moderate to high-risk surgery patients. By leveraging proven ccNexfin system technology, the ClearSight system provides clinicians clarity without the barriers of complexity or invasiveness. Simple for clinicians
The ClearSight system quickly connects to the patient by wrapping an inflatable cuff around the finger. The simplicity of the ClearSight system gives you noninvasive access to automatic, up-to-the-minute hemodynamic information for a broader patient population.
Leverages validated technology
Used as the standard for monitoring in space for decades, ccNexfin noninvasive technology (volume clamp, Physiocal) has been extensively validated against gold-standard monitoring technologies. Several studies have validated the ability of noninvasive ccNexfin technology to reliably track continuous blood pressure, absolute cardiac output and continuous cardiac output.
Advanced hemodynamic monitoring extended to moderate-risk patients
The ClearSight system enables you to expand advanced hemodynamic monitoring to your moderate to high-risk surgery patients — including elderly or obese patients — enabling you to make more informed decisions regarding volume administration.
Flow parameters provided, such as SV and SVV, have been shown to be more dynamic, and sensitive and specific for predicting fluid responsiveness than conventional, pressure-based parameters. These parameters are central to Perioperative Goal-Directed Therapy (PGDT) protocols and, when used together, are key to guiding optimal volume administration in patients at risk of developing complications.

The ClearSight System
A simple, noninvasive approach to monitoring key hemodynamic parameters.
- Stroke Volume (SV)
- Stroke Volume Variation (SVV)
- Cardiac Output (CO)
- Systemic Vascular Resistance (SVR)
- continuous Blood Pressure (cBP)

Noninvasive simplicity. Next-generation clarity.
Edwards Lifesciences ClearSight system is comprised of the ClearSight finger cuff and EV1000 clinical platform. The system presents SV, SVV, CO, SVR and continuous BP clearly and simply on the EV1000 monitor. Easy-to-use touch screens allow selection of the parameters most meaningful for each clinical situation. This intuitive display of fundamental information minimizes unknowns and allows you to more accurately determine your patient’s fluid status.

Visual clinical support
Advanced hemodynamic parameters are presented in a visually simplified manner. Color-based indicators communicate patient status at a glance, and visual clinical support screens allow for immediate recognition and increased understanding of rapidly changing clinical situations.

Historical milestones

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1967</td>
<td>Volume clamp method to measure blood pressure invented by Jan Peňáz</td>
</tr>
<tr>
<td>1977</td>
<td>TNO, a high-profile Dutch research institute, starts development of noninvasive blood pressure</td>
</tr>
<tr>
<td>2005</td>
<td>BMEYE was founded as a spin-off from TNO</td>
</tr>
<tr>
<td>2007</td>
<td>Market introduction of Nexfin system with CO-Trek to non-invasively monitor blood pressure and cardiac output</td>
</tr>
<tr>
<td>2014</td>
<td>Market introduction of ClearSight integrated into the EV1000 clinical platform</td>
</tr>
</tbody>
</table>
The ClearSight system extends continuous hemodynamic monitoring to a broader patient population, including your moderate to high-risk surgery patients. By leveraging proven ccNexfin system technology, the ClearSight system provides clinicians clarity without the barriers of complexity or invasiveness.

Simple for clinicians
The ClearSight system quickly connects to the patient by wrapping an inflatable cuff around the finger. The simplicity of the ClearSight system gives you noninvasive access to automatic, up-to-the-minute hemodynamic information for a broader patient population.

Leverages validated technology
Used as the standard for monitoring in space for decades, ccNexfin noninvasive technology (volume clamp, Physiocal) has been extensively validated against gold-standard monitoring technologies. Several studies have validated the ability of noninvasive ccNexfin technology to reliably track continuous blood pressure, absolute cardiac output and continuous cardiac output.

Advanced hemodynamic monitoring extended to moderate-risk patients
The ClearSight system enables you to expand advanced hemodynamic monitoring to your moderate to high-risk surgery patients — including elderly or obese patients — enabling you to make more informed decisions regarding volume administration.

Flow parameters provided, such as SV and SVV, have been shown to be more dynamic, and sensitive and specific for predicting fluid responsiveness than conventional, pressure-based parameters. These parameters are central to Perioperative Goal-Directed Therapy (PGDT) protocols and, when used together, are key to guiding optimal volume administration in patients at risk of developing complications.
With the integration of the next-generation ClearSight finger cuff into the EV1000 clinical platform, a single platform can now be utilized with both noninvasive and minimally-invasive hemodynamic monitoring options, such as the FloTrac sensor. The ClearSight system also sends an analog pressure to visualize noninvasive BP on a bedside monitor. Edwards has taken this integrated system approach to protect the accuracy of the clinical information and the corresponding quality of patient care.

Helping to advance the care of the acutely ill for 40 years, Edwards Lifesciences seeks to provide the valuable information you need, the moment you need it. Through continuing collaboration with you, ongoing education and our never-ending quest for advancement, our goal is to deliver clarity in every moment.

### References


For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards Lifesciences devices placed on the European market, meet the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC, and bear the CE marking of conformity. Edwards, Edwards Lifesciences, the stylized E logo, cNexfin, ClearSight, EV1000, FloTrac and Nexfin are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2014 Edwards Lifesciences Corporation. All rights reserved. AR11578

---

### ClearSight System

<table>
<thead>
<tr>
<th>Description</th>
<th>Model No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ClearSight Finger Cuff Small Multi Pack</td>
<td>CSCS</td>
</tr>
<tr>
<td>ClearSight Finger Cuff Medium Multi Pack</td>
<td>CSCM</td>
</tr>
<tr>
<td>ClearSight Finger Cuff Large Multi Pack</td>
<td>CSCL</td>
</tr>
<tr>
<td>EV1000 Clinical Platform</td>
<td>EV1000Ni</td>
</tr>
</tbody>
</table>

Connectivity via IFM out through a serial connection, HIL7 through an Ethernet connection or HIL7 Integration Engine.